Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism

Treatment of venous thromboembolism: duration and new options

“…The low intensity group had 1.1 per 100 person-years of major bleeding, versus 0.9 per 100 person-years in the regular intensity group. Both rates of recurrent VTE and major bleeding were relatively low in the latter study when compared to rates observed in other studies, in which 10% recurrent VTE during the first year after complete discontinuation of anticoagulation 15 and 3-4% major bleeding per year 11 was observed. In spite of this potential patient selection in the latter study, it has been argued that the optimal intensity of VKA treatment in patients with VTE is now settled at a target INR of 2.0-3.0 28…”

Treatment of venous thromboembolism: duration and new options

“…The low intensity group had 1.1 per 100 person-years of major bleeding, versus 0.9 per 100 person-years in the regular intensity group. Both rates of recurrent VTE and major bleeding were relatively low in the latter study when compared to rates observed in other studies, in which 10% recurrent VTE during the first year after complete discontinuation of anticoagulation 15 and 3-4% major bleeding per year 11 was observed. In spite of this potential patient selection in the latter study, it has been argued that the optimal intensity of VKA treatment in patients with VTE is now settled at a target INR of 2.0-3.0 28…”

Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials

“…It should be realized that the regimen of LMWH followed by VKAs is very effective with a relative reduction in recurrent VTE of 80% to 90% compared with no or inadequate treatment. 8,9 As a consequence, all phase 3 trials were designed as noninferior studies for efficacy. Taken together, the observed comparable efficacy of DOACs should reassure the clinician that these agents are effective in all subgroups analyzed.…”

Dynamics of Residual Venous Obstruction after Electrical Stimulation of Crural Muscles following the Completion of the Standard Course of Anticoagulation Therapy in Patients with Postthrombotic Syndrome: the Results of the Comparative Non-Randomized Study

“…Предшествующие работы продемонстрировали, что продленное применение АВК позволяет снизить, но не полностью устранить угрозу повторного тромбообразования у пациентов с РВО [15,19]. В то же время при пролонгированном использовании АВК за пятикратным снижением риска рецидива венозного тромбоза кроется увеличение в 2,5 раза опасности больших кровотечений, в том числе фатальных [31]. Новые оральные антикоагулянты в рамках выполненных исследований продемонстрировали улучшенный профиль безопасности по срав-…”

Treatment of venous thromboembolism: duration and new options

“…The low intensity group had 1.1 per 100 person-years of major bleeding, versus 0.9 per 100 person-years in the regular intensity group. Both rates of recurrent VTE and major bleeding were relatively low in the latter study when compared to rates observed in other studies, in which 10% recurrent VTE during the first year after complete discontinuation of anticoagulation 15 and 3-4% major bleeding per year 11 was observed. In spite of this potential patient selection in the latter study, it has been argued that the optimal intensity of VKA treatment in patients with VTE is now settled at a target INR of 2.0-3.0 28…”

Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials

“…It should be realized that the regimen of LMWH followed by VKAs is very effective with a relative reduction in recurrent VTE of 80% to 90% compared with no or inadequate treatment. 8,9 As a consequence, all phase 3 trials were designed as noninferior studies for efficacy. Taken together, the observed comparable efficacy of DOACs should reassure the clinician that these agents are effective in all subgroups analyzed.…”

Dynamics of Residual Venous Obstruction after Electrical Stimulation of Crural Muscles following the Completion of the Standard Course of Anticoagulation Therapy in Patients with Postthrombotic Syndrome: the Results of the Comparative Non-Randomized Study

“…Предшествующие работы продемонстрировали, что продленное применение АВК позволяет снизить, но не полностью устранить угрозу повторного тромбообразования у пациентов с РВО [15,19]. В то же время при пролонгированном использовании АВК за пятикратным снижением риска рецидива венозного тромбоза кроется увеличение в 2,5 раза опасности больших кровотечений, в том числе фатальных [31]. Новые оральные антикоагулянты в рамках выполненных исследований продемонстрировали улучшенный профиль безопасности по срав-…”

Treatment of venous thromboembolism: duration and new options

“…The low intensity group had 1.1 per 100 person-years of major bleeding, versus 0.9 per 100 person-years in the regular intensity group. Both rates of recurrent VTE and major bleeding were relatively low in the latter study when compared to rates observed in other studies, in which 10% recurrent VTE during the first year after complete discontinuation of anticoagulation 15 and 3-4% major bleeding per year 11 was observed. In spite of this potential patient selection in the latter study, it has been argued that the optimal intensity of VKA treatment in patients with VTE is now settled at a target INR of 2.0-3.0 28…”

Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials

“…It should be realized that the regimen of LMWH followed by VKAs is very effective with a relative reduction in recurrent VTE of 80% to 90% compared with no or inadequate treatment. 8,9 As a consequence, all phase 3 trials were designed as noninferior studies for efficacy. Taken together, the observed comparable efficacy of DOACs should reassure the clinician that these agents are effective in all subgroups analyzed.…”

Dynamics of Residual Venous Obstruction after Electrical Stimulation of Crural Muscles following the Completion of the Standard Course of Anticoagulation Therapy in Patients with Postthrombotic Syndrome: the Results of the Comparative Non-Randomized Study

“…Предшествующие работы продемонстрировали, что продленное применение АВК позволяет снизить, но не полностью устранить угрозу повторного тромбообразования у пациентов с РВО [15,19]. В то же время при пролонгированном использовании АВК за пятикратным снижением риска рецидива венозного тромбоза кроется увеличение в 2,5 раза опасности больших кровотечений, в том числе фатальных [31]. Новые оральные антикоагулянты в рамках выполненных исследований продемонстрировали улучшенный профиль безопасности по срав-…”